<!– Name:DistributionId Value:8738609 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value:5557 –> <!– Name:CustomerId Value:1095645 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:664fb68b-bb59-43c2-8944-b0422d3b13b2 –>
NEWARK, Del, Jan. 30, 2023 (GLOBE NEWSWIRE) — The Point-Of-Care Molecular Diagnostics Market is predicted to secure a valuation of US$ 4.4 billion in 2023 and is rising to US$ 11.1 billion by 2033. The market is estimated at a CAGR of 9.7% during the forecast period.
Rising infectious and chronic diseases, such as cardiovascular, diabetes, and COVID-19, are increasing the adoption of point-of-care molecular diagnostics. The demand for point-of-care molecular diagnostics is further increasing due to delayed testing results and high costs. Moreover, point-of-care molecular diagnostics manufacturers are growing the market opportunities by increasing production in the global market.
The growing advanced technology, diagnostic tests, preventive medicine, and knowledge of molecular mechanisms are driving the market growth. Furthermore, the adoption of point-of-care molecular diagnostics by laboratory specialist for sequencing DNA & multi-gene are expanding the market size. These diagnostics rapidly show the results with accuracy and are estimated to increase the sales of point-of-care molecular diagnostics.
Request Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-14279
Increasing respiratory, gastrointestinal, and sexually transmitted diseases are advancing the market growth. Emerging economies, government initiatives, and low-cost POC molecular diagnostics are the prime factors that propel market opportunities.
Factors Restraining the Market Growth
The market is going through a growth decline due to a few factors which are given below:
The dearth of consciousness about healthcare products, and poor penetration of advanced healthcare devices restrain market growth. The unavailability of advanced devices and the absence of government policies must gain market growth in developing countries.
Which Technology Category Booms the Market Growth?
The RT-PCR category dominates the global market with its remarkable CAGR of 9.2% during the foreseen time. The adoption of RT-PCR is rising due to the rise in tests such as genomics, COVID-19, proteomics, and others. It is a real-time system that shows results immediately, has high sensitivity, and costs efficiently. Due to the significant growth of infectious patients, healthcare providers are accelerating the demand for RT-PCR to provide patients with relevant data immediately.
Request Customization @ https://www.futuremarketinsights.com/customization-available/rep-gb-14279
- The point-of-care molecular diagnostics market is expected to have a valuation of US$ 11.1 billion by 2033.
- With a CAGR of 9.7%, the global market increasing from 2022 to 2033.
- The United States market is anticipated to capture a CAGR of 9.5% through 2033.
- With a CAGR of 8.8%, the United Kingdom market significantly uplifts during the forecast period.
- China market is expected to expand at a CAGR of 9.1% over the forecast period.
- Japan market is likely to capture a CAGR of 8.2% from 2023 to 2033.
Key Companies Profiled:
- Abbott Laboratories
- Hoffmann-La Roche Ltd.
- BioMérieux S.A.
- Danaher Corporation
- Quidel Corporation
- QIAGEN N.V.
- Co-Diagnostics, Inc.
- Biocartis NV (Belgium)
- Meridian Bioscience, Inc.
- Thermo Fisher Scientific, Inc.
Who is winning?
Key players fragment the global market by contributing an impressive role. These players are bringing new ideas and adapting them to build advanced products, which in turn surging market opportunities. Growing technologies, including Artificial Intelligence and the Internet of Things, have surpassed market growth in recent years.
By accepting these technologies, key players welcome better detection machines and equipment as per patients’ requirements. They further follow several effective marketing strategies such as partnerships, mergers, acquisitions, agreements, and product launches.
Buy Now/Purchase @ https://www.futuremarketinsights.com/checkout/14279
- In Feb 2022, Sense Biodetection signed an agreement with Una Health to distribute COVID-19 testing equipment.
- In Dec 2021, FIND Company invested a valuation of US$ 21 million in S.D. Biosensor, Biomeme, Quaife, and Bioneer for manufacturing, developing and launching an affordable COVID-19 testing detector.
- A healthcare provider BioMérieux agreed to partner with Africa Medical Supplies Platform in Oct 2020 to supply premium quality COVID-19 diagnostic solutions.
- Abbott Laboratories announced its new COVID-19 detection product which can deliver results within minutes, in March 2020.
- In Oct 2018, QIAGEN agreed to enhance its portfolio with STAT-Dx to provide its customers with a next-generation PCR system.
Point-of-care Molecular Diagnostics Market Segmentation by Category –
By Products & Services:
- Assays & Kits
- Instruments &Analyzers
- Software & Services
- Other Technologies
- Respiratory Diseases
- Sexually Transmitted Diseases
- Hospital-acquired Infections
- Gastrointestinal Disorders
- Other Applications
By End User:
- Physicians’ Offices
- Hospitals & ICUs
- Research Institutes
- Other End Users
Table of Content-
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
View Full Report @ https://www.futuremarketinsights.com/reports/point-of-care-molecular-diagnostics-market
Have a Look at Related Research Reports of Healthcare Domain:
Lab Automation Market Size – In 2023, the lab automation market is estimated to be worth US$ 2.1 billion. With the increasing adoption of lab automation across various end-use verticals, the lab automation market is expected to grow at a CAGR of 10.1% during the forecast period, reaching US$ 5.5 billion by 2033
Biosensors Market Share – Newly-released Biosensors Market analysis report by Future Market Insights shows that the global market size of the Biosensors Market in 2022 was held at US$ 24.5 Billion. With a CAGR of 9.5% during 2023 to 2033
Aarskog Scott Syndrome Treatment Market Growth – The global Aarskog Scott syndrome treatment market is expected to garner a market value of US$ 3.20 Billion in 2023 and is expected to accumulate a market value of US$ 6 Billion by registering a CAGR of 6.5% in the forecast period 2023 to 2033
Arthrogryposis Management Market Trends – The global arthrogryposis management market is expected to garner a market value of US$ 250 Million in 2023 and is expected to accumulate a market value of US$ 447.41 Million by registering a CAGR of 6% in the forecast period 2023 to 2033
Adrenogenital Syndrome Treatment Market Forecast – The global adrenogenital syndrome treatment market is expected to reach US$ 12.81 Billion in 2023 and is projected to exhibit a CAGR of 5.6% from 2023 to 2033. Natural treatments, minimally invasive surgeries, and new therapies are expected to drive growth.
About Us :
Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
LinkedIn| Twitter| Blogs | YouTube
For Sales Enquiries: [email protected]